Annexon Target of Unusually High Options Trading (NASDAQ:ANNX)

Annexon, Inc. (NASDAQ:ANNX) was the recipient of some unusual options trading activity on Wednesday. Investors acquired 2,592 call options on the company. This represents an increase of approximately 244% compared to the average daily volume of 754 call options.

Key Stories Impacting Annexon

Here are the key news stories impacting Annexon this week:

• Positive Sentiment: Citizens JMP upgraded Annexon from “underperform” to “market perform,” reducing a bearish rating and signaling a more balanced view of the company’s prospects. Benzinga
• Positive Sentiment: Tanruprubart generated early positive results in the FORWARD study for Guillain-Barré syndrome, with improvements in patient strength and disability. Annexon expects to submit a U.S. Biologics License Application in the fourth quarter of 2026, an important regulatory catalyst. Annexon Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Annexon expanded the Phase 3 ARCHER II trial of vonaprument by adding a Month 24 dual primary endpoint alongside the Month 15 endpoint. The structure could give the drug two independent opportunities to demonstrate vision-loss protection in geographic atrophy. Month 15 data remain expected in the fourth quarter of 2026. Annexon Expands Vonaprument Phase 3 Program
• Positive Sentiment: A credit facility of up to $200 million, including $50 million initially drawn, is expected to extend Annexon’s cash runway into 2028 and fund upcoming clinical and regulatory milestones.
• Neutral Sentiment: Unusually heavy call-option buying and recent insider purchases may indicate speculative or favorable positioning, but these trading signals do not guarantee sustained stock appreciation.
• Negative Sentiment: Second-quarter adjusted loss was $0.28 per share, wider than analysts’ expected $0.24 loss. The miss likely contributed to selling, particularly as research and development expenses rose to $46.6 million and the company remains unprofitable. Annexon Shares Fall as Second-Quarter Loss Exceeds Forecasts
• Negative Sentiment: The Month 24 ARCHER II results are not expected until the third quarter of 2027, leaving investors exposed to a long wait and substantial clinical and regulatory risk.

Insiders Place Their Bets

In other Annexon news, Director Muneer A. Satter bought 613,497 shares of the business’s stock in a transaction that occurred on Thursday, May 28th. The shares were purchased at an average cost of $5.41 per share, with a total value of $3,319,018.77. Following the purchase, the director directly owned 10,342,134 shares in the company, valued at approximately $55,950,944.94. This represents a 6.31% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 10.31% of the stock is currently owned by insiders.

Institutional Trading of Annexon

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Wealth Enhancement Advisory Services LLC boosted its position in shares of Annexon by 13.6% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 19,553 shares of the company’s stock worth $100,000 after acquiring an additional 2,348 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Annexon by 65.6% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,033 shares of the company’s stock valued at $35,000 after acquiring an additional 2,785 shares during the last quarter. Susquehanna Portfolio Strategies LLC raised its position in shares of Annexon by 0.8% during the 4th quarter. Susquehanna Portfolio Strategies LLC now owns 356,619 shares of the company’s stock worth $1,790,000 after acquiring an additional 2,875 shares in the last quarter. ProShare Advisors LLC raised its position in shares of Annexon by 21.7% during the 4th quarter. ProShare Advisors LLC now owns 24,698 shares of the company’s stock worth $124,000 after acquiring an additional 4,410 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its position in shares of Annexon by 3.6% during the 1st quarter. The Manufacturers Life Insurance Company now owns 134,786 shares of the company’s stock worth $747,000 after acquiring an additional 4,684 shares in the last quarter.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on ANNX shares. HC Wainwright reaffirmed a “buy” rating and set a $14.00 price objective on shares of Annexon in a research report on Monday, July 20th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Annexon in a report on Monday, July 13th. Needham & Company LLC boosted their target price on Annexon from $11.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, July 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Annexon in a report on Friday, July 17th. Finally, Citigroup began coverage on Annexon in a research report on Tuesday, July 21st. They issued a “market underperform” rating on the stock. Five research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Annexon presently has a consensus rating of “Hold” and a consensus target price of $15.33.

Annexon Trading Down 1.3%

Shares of NASDAQ:ANNX opened at $5.26 on Friday. Annexon has a 52 week low of $2.03 and a 52 week high of $7.18. The company’s 50 day moving average is $5.35 and its two-hundred day moving average is $5.51. The company has a market cap of $861.80 million, a PE ratio of -4.53 and a beta of 1.18.

Annexon (NASDAQ:ANNX) last announced its quarterly earnings data on Wednesday, August 12th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.04). As a group, equities research analysts expect that Annexon will post -0.92 EPS for the current year.

About Annexon

Annexon Inc is a clinical-stage biotechnology company focused on the discovery and development of complement-targeted therapies for patients with neurodegenerative and neuroimmune diseases. The company’s research platform centers on the inhibition of the C1 complex, a key initiator of the classical complement pathway implicated in several rare and life-threatening disorders. By selectively targeting upstream complement activation, Annexon aims to prevent the aberrant immune-mediated damage that characterizes conditions such as Guillain-Barré syndrome (GBS) and autoimmune neuropathies.

At the core of Annexon’s pipeline is ANX005, a humanized monoclonal antibody directed against the C1q subcomponent, currently in Phase 2 clinical trials for acute GBS and chronic neurodegenerative indications.